Houdin Dehnad, Ph.D.  

  • 20+ years Med Tech early technology development
  • Focus on implant material design in embolic coils, stents and polymer materials
  • Previous experiences with Alza, Micrus & Guidant
  • BS Chemical Engineering, Washington University; MS and Ph.D. University of Minnesota 

Bohdan Chopko, MD, PhD

  • Professor of Neurosurgery and Complex Spine—Stanford University
  • Doctor of Medicine, Northeastern Ohio Universities College of Medicine
  • Ph.D. Neuroscience Kent State University
  • Resident, neurological surgery training program, UC San Diego 

There is a significant clinical need to prevent bacteria from contaminating patients upon medical device implantation.

Silver Bullet Therapeutics has developed OrthoFuzIon™ with a regulatory-cleared silver ionization coating for an antimicrobial device implant.

The CMS “Bundled Payments for Care Improvement” (BPCI) may be a dramatic driving force for market adoption of OrthoFuzIon™ and Galvanis™ technology. 

​Six years of development, testing and animal trials have enabled us to perfect our technology. 


Paul Chirico, President & CEO

  • 30+  years in Med Tech, 20+ years in orthopedics/spine
  • Founder/CEO SpineAlign Medical
  • Previous experiences with Micrus Endovascular, Incyte Genomics & Avocet Medical
  • BS Biology/MBA Accounting, Santa Clara University 

Why Silver Bullet?

About Silver Bullet

​​Silver Bullet is developing OrthoFuzIon™, an antimicrobial coating based on proprietary silver ionization technology designed to prevent contaminations associated with medical device implants.